-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Outlook Therapeutics, Lowers Price Target to $21

Benzinga·06/06/2025 10:51:37
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and lowers the price target from $24 to $21.